Skip to main content

Latest News

SUBSEQUENT DECISION NOT TO RECOMMEND MAVENCLAD®

23rd April 2018

The Pharmaceutical Benefits Advisory Committee (PBAC) have announced they have not recommended the listing of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).

Read More
article.heroMedia.text

MSWA supporting people living with Parkinson’s

11th April 2018

For two years Kent Piercy developed an increasing stiffness and slowness in both arms and a reduced swing in his right arm. Naturally concerned about these changes, Kent saw a neurologist early last year, and at the age of 74 was diagnosed with tremor-dominant idiopathic Parkinson’s.

Read More
article.heroMedia.text

New UV research gives hope to people with MS

14th March 2018

31-year-old Chloe Baker has been living with MS and embracing the everyday challenges that comes with that diagnosis. For Chloe and many others with MS in Perth and around the world, the research by Perth-based researcher Professor Prue Hart is giving them hope. In a world-first, the research has proven to delay the development of MS in high-risk individuals using narrowband UVB treatment. 

Read More
article.heroMedia.text

$1 million research funding into brain plasticity

12th March 2018

MSWA has recognised the importance of the cutting-edge research being carried out by Associate Professor Jenny Rodger and is investing $1 million to fund her work over the next four years, in her new role as the Senior Research Fellow in Brain Plasticity at the Perron Institute. Jenny and her team will carry out research to understand the mechanisms of brain plasticity to improve the quality of life in patients with neurological conditions.

Read More
article.heroMedia.text

Show your support

With your support, MSWA are delivering real things to real people living with neurological conditions in Western Australia.

It is easy to show your support. You can buy a raffle ticket, a lottery ticket, even an entertainment book, or simply donate.


Find out more.